Individual Article: Efficacy of Over-The-Counter Cream in Reducing Eczema Signs

医学 养生 耐受性 不利影响 特应性皮炎 皮肤科生活质量指数 湿疹面积及严重程度指数 红斑 皮疹 生活质量(医疗保健) 皮肤病科 内科学 疾病 护理部
作者
Adelaide A. Hebert,Mathieu Grivet-Seyve,Sarah Anjuwon,Nathalie Piccardi,Nadège Lachmann,Agustin Cruz,Christine Emesiani
出处
期刊:Journal of Drugs in Dermatology [SanovaWorks]
卷期号:22 (10): SF388641s5-SF388641s9
标识
DOI:10.36849/jdd.8641
摘要

Eczema, or atopic dermatitis (AD), is a chronic relapsing skin disease associated with unpredictable flares of erythema, rash, and pruritus. AD arises from a combination of immune system dysregulation and abnormal skin barrier function. Skin barrier support with proper skincare regimens have a central role in management.This was a multi-center, 12-week in-use study of a skincare regimen in children and adults with mild-to-moderate eczema (6-16) on the Patient-Oriented Eczema Measure (POEM), and ≥2 flares within 3 months prior to screening. The regimen included Itch Relief Gel, Eczema Soothing Lotion, and Flare Relief Cream. Efficacy assessments included POEM, ItchyQuant, Eczema Area and Severity Index (EASI), Quality of Life and digital photography, along with gathering of adverse events and cutaneous tolerability.34 subjects completed the study. In 12 weeks, mean POEM scores improved from 9.7 to 5.3, and EASI scores improved by 17.9% (P<0.05 vs baseline). Additionally, mean ItchyQuant scores showed that pruritus was significantly improved from 5.4 at baseline to 2.7 at week 12 (P<0.05). The number of flares decreased from 4.2 to 3.2 after 12 weeks of regimen application (P<0.05 vs 12 weeks before baseline). Quality-of-life measures also showed improvement in both children and adults from baseline (P<0.05). There were no related adverse events, the regimen was well tolerated, and participants had positive perceptions of the regimen.12-week use of this OTC skincare regimen resulted in significant improvements in EASI, POEM, and ItchyQuant scores, a reduced number of flares, and improved quality of life. J Drugs Dermatol. 2023;22:10(Suppl 2):s21-26.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
东溟渔夫发布了新的文献求助10
刚刚
刚刚
xzy998发布了新的文献求助30
1秒前
1秒前
结实星星应助跑快点采纳,获得20
1秒前
2秒前
2秒前
科研通AI2S应助太阳当空照采纳,获得10
2秒前
茜茜发布了新的文献求助10
3秒前
怡然冰蓝完成签到,获得积分10
4秒前
安心完成签到,获得积分10
4秒前
pokikiii发布了新的文献求助10
5秒前
5秒前
6秒前
polaris发布了新的文献求助10
6秒前
7秒前
7秒前
Ava应助科研通管家采纳,获得10
8秒前
英姑应助科研通管家采纳,获得10
9秒前
leaolf应助科研通管家采纳,获得10
9秒前
华仔应助科研通管家采纳,获得10
9秒前
ding应助科研通管家采纳,获得100
9秒前
白榆应助科研通管家采纳,获得10
9秒前
仙笛童神发布了新的文献求助10
9秒前
科研通AI5应助科研通管家采纳,获得10
9秒前
斯文败类应助科研通管家采纳,获得10
9秒前
123完成签到,获得积分10
9秒前
慕青应助科研通管家采纳,获得10
9秒前
orixero应助科研通管家采纳,获得10
9秒前
天天快乐应助东溟渔夫采纳,获得10
9秒前
bkagyin应助科研通管家采纳,获得10
9秒前
王雪应助科研通管家采纳,获得10
10秒前
泡利关注了科研通微信公众号
10秒前
白榆应助科研通管家采纳,获得10
10秒前
10秒前
Akim应助科研通管家采纳,获得10
10秒前
无花果应助科研通管家采纳,获得30
10秒前
科研通AI5应助科研通管家采纳,获得10
10秒前
我是老大应助科研通管家采纳,获得100
10秒前
科研通AI6应助科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
줄기세포 생물학 1000
Biodegradable Embolic Microspheres Market Insights 888
Quantum reference frames : from quantum information to spacetime 888
Pediatric Injectable Drugs 500
Instant Bonding Epoxy Technology 500
ASHP Injectable Drug Information 2025 Edition 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4403373
求助须知:如何正确求助?哪些是违规求助? 3889951
关于积分的说明 12106422
捐赠科研通 3534584
什么是DOI,文献DOI怎么找? 1939503
邀请新用户注册赠送积分活动 980305
科研通“疑难数据库(出版商)”最低求助积分说明 877188